

Anthem Biosciences Limited

(Formerly known as Anthem Biosciences Pvt. Ltd.)

49, F1 & F2, Canara Bank Road,
Bommasandra Industrial Area, Phase - I
Bommasandra, Bengaluru - 560 099
Karnataka, India
CIN : L24233KA2006PLC039703
Tel : + 91 80 6672 4000
www.anthembio.com

Date: May 19, 2026

To,
BSE Limited,
20th Floor, P.J. Towers,
Dalal Street,
Mumbai - 400001.
BSE Scrip Code: 544449

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051
NSE Scrip Symbol: ANTHEM

Subject: Press Release on the Audited Consolidated Financial Results for the quarter and year ended March 31, 2026.

Dear Sir/Ma'am

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed a copy of the Press Release on the Audited Consolidated Financial Results of the Company for the quarter and year ended March 31, 2026.

The same is also available on the Company's website at <https://anthembio.com/investors/>

We request you to kindly take the same on record.

Thanking you,

Yours truly,
For Anthem Biosciences Limited
(Formerly known as Anthem Biosciences Private Limited)

Divya Prasad
Company Secretary & Compliance Officer
Membership No: A41438

Press Release: Anthem FY26 and Q4FY26 Results

***For FY26, Consolidated Revenue from Operations stood at ₹21,243 Mn.
EBITDA for FY26 was ₹9,896 Mn at 43.4% EBITDA Margins.
PAT at ₹5,918 Mn, with PAT margins at 26.0%.***

***Consolidated Revenue from Operations for the quarter stood at ₹6,109 Mn.
EBITDA for the quarter was ₹3,184 Mn at 48.1% EBITDA Margins.
PAT at ₹1,898 Mn, with PAT margins at 28.7%.***

Bengaluru, May 19, 2026: Anthem Biosciences Limited (BSE: 544449 | NSE: ANTHEM | INE0CZ201020), an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (“CRDMO”), today announced Audited Consolidated Financial Results for the quarter and year ended March 31, 2026 as approved by its Board of Directors.

FY26 and Q4FY26 Financial Highlights:

Particulars (₹ Mn)	Q4FY26	Q4FY25	YoY	Q3FY26	QoQ	FY26	FY25	YoY
Revenue from Operations	6,109	4,832	26.4%	4,232	44.4%	21,243	18,446	15.2%
<i>CRDMO</i>	5,128	3,923	30.7%	3,332	53.9%	17,727	15,061	17.7%
<i>Specialty Ingredients</i>	981	909	7.9%	899	9.1%	3,516	3,385	3.9%
Other Income	512	140	265.7%	335	52.8%	1,558	857	81.8%
Total Revenues	6,622	4,973	33.2%	4,567	45.0%	22,801	19,303	18.1%
EBITDA	3,184	2,092	52.2%	1,907	66.9%	9,896	7,566	30.8%
Profit before tax before exceptional items	2,769	1,783	55.3%	1,558	77.8%	8,486	6,569	29.2%
Exceptional Items – impact of new labour code	(10)	n.a.	n.a.	254	n.a.	244	n.a.	n.a.
Profit before tax after exceptional items	2,779	1,783	55.9%	1,305	112.9%	8,242	6,569	25.5%
Profit after tax	1,898	826	129.8%	928	104.5%	5,918	4,513	31.1%

FY26 Key Financial Highlights:

- Consolidated Revenue from Operations for the full year ended Mar 31, 2026 was ₹21,243 Mn
 - *CRDMO business delivered ₹17,727 Mn revenues*
 - *Specialty Ingredients delivered ₹3,516 Mn revenues*
- EBITDA was ₹9,896 Mn, with EBITDA margins at 43.4%
 - *EBITDA includes Other Income of ₹1,558 Mn (FY25: ₹857 Mn)*
 - *Other Operating Income on account of forex gain (net) and RoDTEP incentives is ₹634 Mn (FY25: ₹129 Mn)*
 - *Financial and other Non-Operating Income is ₹924 Mn (FY25: ₹728 Mn)*
- PBT before exceptions items was ₹8,486 Mn
 - *Exceptional item on account of new labour code impact was ₹244 Mn.*
 - *On November 21, 2025, the Government of India notified four new Labour Codes. The Company has assessed and made a provision, as an Exceptional Item consistent with the guidance provided by the Institute of Chartered Accountants of India, in the financial results for the quarter and nine months ended December 31, 2025. During the quarter ended 31 March 2026, the management reassessed the impact of the new labour code change based on the revised remuneration structure, which resulted in a credit in the consolidated financial results. Accordingly, for the year ended 31 March 2026, the net expense recognized in "Exceptional Item" amounts to Rs. 244 million in the Consolidated financial results. In case of any further clarification from the Government on other aspects of the Labour Codes, the Company will evaluate and account for differential impact, if any, in subsequent periods.*
- PAT (Profit After Tax) was ₹5,918 Mn, with PAT margins at 26.0%
- Net Cash position as of Mar 31, 2026 is ₹13,743 Mn

Q4FY26 Key Financial Highlights:

- Consolidated Revenue from Operations was ₹6,109 Mn for the quarter
 - CRDMO business delivered ₹5,128 Mn revenues
 - Specialty Ingredients delivered ₹981 Mn revenues
- EBITDA was ₹3,184 Mn, with EBITDA margins at 48.1%
 - EBITDA for Q4FY26 includes Other Income of ₹335 Mn (Q4FY25: ₹140 Mn)
 - Other Operating Income on account of forex gain (net) and RoDTEP incentives is ₹229 Mn (Q4FY25: loss of ₹82 Mn)
 - Financial and other Non-Operating Income is ₹283 Mn (Q4FY25: ₹222 Mn)
- PBT before exceptions items was ₹2,769 Mn
 - Exceptional item on account of new labour code impact was a credit of ₹10 Mn.
- PAT (Profit After Tax) was ₹1,898 Mn, with PAT margins at 28.7%

Commenting on the results, **Ajay Bhardwaj, Chairman, MD and CEO, Anthem Biosciences Limited**, said: “We ended the financial year 2025–26 on a strong note, with our highest revenue quarter ever in Q4FY26. We delivered a Revenue growth of 26% YoY for the quarter and 15% YoY for the financial year 2025-26. Anthem’s commitment to prudent cost management and focus on long-term value creation has enabled us to expand profitability margins while delivering this revenue growth. Our EBITDA and PAT for the year grew by more than 30% in line with our growth aspirations. The Company continues to maintain a healthy financial position and remains committed to delivering sustainable growth across all business segments. As we step into financial year 2026–27, our priorities remain clear: **to build one of the most agile, science-led, and future-ready CRDMO platforms in the world.**”

Earnings Call:

Anthem Biosciences Limited will conduct earnings call at 11:00 am (IST) on 20th May, 2026 to discuss the financial and business performance of the quarter. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time.

Date and Time: 20th May 2026, 11:00 am (IST) //00:30 am (USA)/ 6:30 am (UK)/1:30 pm (SGT/HKT)

Universal Dial-in +91 22 6280 1366 / +91 22 7115 8267

International Dial-in Singapore: 8001012045 | HK: 800964448 | USA: 186674 62133 | UK: 08081011573

Diamond Pass link [Diamond Pass Registration](#)

About Anthem: Incorporated in Bangalore on June 13, 2006, Anthem is an innovation-driven and technology-focused CRDMO with fully integrated operations spanning across drug discovery, development and manufacturing. Anthem is one of the few companies in India with integrated New Chemical Entity (“NCE”) and New Biological Entity (“NBE”) capabilities across drug discovery, development, and commercial manufacturing. As a one-stop service provider, Anthem serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally. With the three pillars of innovation and technology, high quality standards, and a customer- first approach, Anthem is committed to solving problems in biology and chemistry using technology.

For more information, please visit <https://anthembio.com/investors/>

For further details, please feel free to contact: investors.abl@anthembio.com | anthem@adfactorspr.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects on the Company. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, change in laws and regulations that apply to pharmaceuticals, increasing competition in and changes in political conditions in India. Neither Anthem, nor our directors, assume any obligation to update any forward-looking statement contained in this release. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.